Uveitis is a form of eye inflammation. It affects the middle layer of tissue in the eye wall. Posterior uveitis is the condition that arises when an inflammation of a part of an eye called as choroid. This condition is also be named as choroiditis. This form of uveitis is the rarest of all the types.

The global uveitis treatment market is estimated to account for US$ 648.4 Mn in terms of value in 2020 and is expected to reach US$ 1,036.0 Mn by the end of 2027.

Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/1094

Global Uveitis Treatment Market: Drivers

Approval and launch of new products is expected to propel growth of the global uveitis treatment market over the forecast period. For instance, in December 2019, Alimera Sciences, Inc. received marketing authorization for ILUVIEN in Belgium, The Netherlands, and Luxembourg, for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

Moreover, high prevalence of uveitis is also expected to aid in growth of the market. For instance, the distribution of prevalent uveitis cases was anterior (75%), intermediate (6%), posterior (15%) and panuveitis (4%), according to a study published in April 2019 in the journal Clinical and Experimental Ophthalmology.

Global Uveitis Treatment Market: Restraints

Insufficient funding for R&D in eye health is expected to hinder growth of the global uveitis treatment market. For instance, according to Peter McCluskey, Professor of Clinical Ophthalmology and Eye Health, and Director of Save Sight Institute at the Faculty of Medicine and Health at the University of Sydney, (as reported to MI Vision, an ophthalmic journal, in July 2019), research grants from the National Health and Medical Research Council (Australia) are down from 30% to around 7%.

Global Uveitis Treatment Market: Opportunities

R&D of new products is expected to offer lucrative growth opportunities for players in the global uveitis treatment market. For instance, in May 2020, researchers from National Cheng Kung University, Taiwan, identified a novel role of reactive oxygen species in the pathogenesis of experimental autoimmune uveitis and suggested a potential antioxidant role for the treatment of autoimmune uveitis in the future. Similarly, in June 2020, Tarsius Pharma, a clinical-stage biopharmaceutical company, completed patient enrollment in the companyโ€™s Phase I/II trial of TRS01 in patients with active anterior non-infectious uveitis.

Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/1094

Key Takeaways

Corticosteroids held dominant position in the global uveitis treatment market in 2019, accounting for 21.1% share in terms of value, followed by Monoclonal Antibodies and Antibiotics, respectively. Corticosteroids are a primary treatment options for treating uveitis, and can be administered via multiple routes such as topical, and oral.

Market Trends

Asia Pacific is expected to witness significant growth in the global uveitis treatment market, owing to high prevalence of uveitis in the region. For instance, the incidence of uveitis in Australia was 21.54 per 100โ€‰000 person/years, according to a study published in April 2019 in the journal Clinical and Experimental Ophthalmology.

North America is also expected to witness significant growth in the global uveitis treatment market, owing to high prevalence of autoimmune disorders. For instance, in 2017, nearly 1 million adults were living with multiple sclerosis in the U.S, according to a study by National MS Society, published in February 2019, in the journal Neurology.

Global Uveitis Treatment Market: Competitive Landscape

Major players operating in the global uveitis treatment market include,

  • Allergan, Inc.,
  • Alimera Sciences Inc.,
  • AbbVie Inc.,
  • Clearside Biomedical, Inc.,
  • Eyegate Pharmaceuticals, Inc.,
  • EyePoint Pharmaceuticals, Inc.,
  • Galapagos,
  • Novartis AG,
  • pSivida Corp.,
  • Tarsius Pharma, and
  • Valeant Pharmaceuticals International, Inc.

๐—ฆ๐—ฎ๐—น๐—ฒ ๐—œ๐˜€ ๐—Ÿ๐—ถ๐˜ƒ๐—ฒ!

๐—•๐˜‚๐˜† ๐—ก๐—ผ๐˜„ ๐—ง๐—ผ ๐—š๐—ฒ๐˜ ๐—™๐—น๐—ฎ๐˜ ๐Ÿฏ๐Ÿฌ % ๐—ข๐—ณ๐—ณ

Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/1094

Global Uveitis Treatment Market: Segmentation

  • By Treatment Type
    • Corticosteroids
    • Immunosuppressant
    • Monoclonal Antibodies
    • Cycloplegic Agents
    • Antibiotics
    • Antivirals
    • Antifungal
    • Analgesics
  • By Disease Type
    • Anterior Uveitis
    • Posterior Uveitis
    • Intermediate Uveitis
    • Pan uveitis
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Drug Stores
  • By Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837